Compare TILE & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TILE | OLMA |
|---|---|---|
| Founded | 1973 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 1994 | 2020 |
| Metric | TILE | OLMA |
|---|---|---|
| Price | $28.08 | $21.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $36.00 | ★ $42.00 |
| AVG Volume (30 Days) | 398.6K | ★ 1.1M |
| Earning Date | 05-27-2026 | 04-15-2026 |
| Dividend Yield | ★ 0.28% | N/A |
| EPS Growth | ★ 32.43 | N/A |
| EPS | ★ 1.96 | N/A |
| Revenue | ★ $1,386,854,000.00 | N/A |
| Revenue This Year | $7.00 | N/A |
| Revenue Next Year | $5.46 | N/A |
| P/E Ratio | $14.34 | ★ N/A |
| Revenue Growth | ★ 5.41 | N/A |
| 52 Week Low | $17.31 | $2.86 |
| 52 Week High | $35.11 | $36.26 |
| Indicator | TILE | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 25.72 | 35.63 |
| Support Level | $27.55 | $4.31 |
| Resistance Level | $28.87 | $27.38 |
| Average True Range (ATR) | 1.06 | 1.26 |
| MACD | -0.63 | -0.11 |
| Stochastic Oscillator | 12.92 | 8.15 |
Interface Inc is engaged in the design, production, and sale of carpet tiles. It also provides Luxury Vinyl tiles and rubber flooring. The company mainly targets corporate and noncorporate office markets, including government, education, healthcare, hospitality, and retailers. Its geographical segments include the Americas, Europe, and Asia-Pacific. It has two operating and reportable segments- namely Americas (AMS) and Europe, Africa, Asia and Australia (collectively EAAA). Key revenue is generated from AMS segment.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.